Background: ACTION, a 24-week, prospective, randomized, parallel-group, double-blind study in patients
Introduction
Three cholinesterase inhibitors (ChEIs), rivastigmine, donepezil and galantamine, are approved in the USA for the treatment of mild-to-moderate Alzheimer's disease (AD) [1] [2] [3] [4] . All three are available in oral formulations [1, 3, 4] ; rivastigmine is the only ChEI also approved for transdermal delivery, via a patch [2] . As well as mildto-moderate disease stages, rivastigmine transdermal patch is indicated for severe AD [2] . Oral donepezil is also indicated for moderate-to-severe AD [3] , along with the N-methyl-D-aspartate (NMDA) receptor antagonist, memantine [5] .
Based on memantine's alternative mechanism of action, there is a rationale for considering memantine as an add-on therapy to ChEIs in patients with moderate-to-severe AD. However, despite some positive studies in patients with moderate-to-severe AD, the benefits of combination therapy have yet to be robustly demonstrated [6] . Post-hoc meta-analyses of data from two 24-week, randomized, double-blind, placebo-controlled trials [7, 8] reported that combination therapy with donepezil (10 mg/day) and memantine (20 mg/day) was associated with enhanced efficacy, without marked impact on safety and tolerability, compared with donepezil alone, in patients with moderate or moderate-to-severe AD [9] . However, a 52-week, double-blind, placebo-controlled study reported no significant benefit of adding memantine (20 mg/day) to donepezil (10 mg/day) [10] .
Furthermore, concomitant memantine (up to 20 mg/day) use was not found to have any impact on the efficacy of high-dose 23 mg/day versus 10 mg/day donepezil in a post-hoc analysis of a clinical study in patients with moderate-to-severe AD [11] . In this study, the incidence of treatment-emergent adverse events (AEs) was higher with 23 mg/day donepezil with memantine (80.7%) compared with 23 mg/day donepezil without memantine (69.7%) [11] .
The ACTivities of daily living and cognitION (ACTION) study was a 24-week, randomized, double-blind comparison of 13.3 mg/24 h and 4.6 mg/24 h rivastigmine patch in patients with severe AD [12, 13] . In this study, the high-dose (13.3 mg/24 h) rivastigmine patch showed significantly superior efficacy compared with the low-dose (4.6 mg/24 h) rivastigmine patch on both co-primary endpoints, the Severe Impairment Battery (SIB) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-Severe Impairment Version (ADCS-ADL-SIV) [13] . Given the advanced disease stage of the study population, patients were permitted to use concomitant memantine during the double-blind phase, provided they had been receiving a stable dose for at least 3 months prior to the screening visit [13] . The objective of the current post-hoc analysis of the ACTION study was to investigate the efficacy, safety and tolerability of the high-dose 13.3 mg/24 h versus the low-dose 4.6 mg/24 h rivastigmine patch in patients with severe AD stratified according to their use of concomitant memantine (up to 20 mg/day) during double-blind treatment.
Material and Methods

Study Design and Patients
This was a retrospective post-hoc analysis of the 24-week, prospective, randomized, double-blind, doubledummy, multicenter, US-based, ACTION study (ClinicalTrials.gov Identifier: NCT00948766) [12, 13] .
Detailed methodology of the ACTION study has been published previously [12, 13] . Briefly, patients were male or female, aged ≥50 years, with probable AD (original 1984 National Institute of Neurological and Communicative Disorders and Stroke and AD and Related Disorders Association criteria) [14] , and a MiniMental State Examination (MMSE) [15] score of 3-12, inclusive. Patients were excluded if they had received ChEIs and/or other approved treatments for AD during the previous 2 weeks, with the exception of stable memantine if taken for at least 3 months prior to screening. Eligible patients were randomized in a 1:1 ratio to receive 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch for 24 weeks. Co-primary outcome measures were the change from baseline at Week 24 on the SIB [16] and the ADCS-ADL-SIV [17] . Safety assessments included the incidence of AEs, serious AEs (SAEs), and discontinuations due to AEs or SAEs.
The ACTION study was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. All patients, or their legally authorized representative, provided written informed consent prior to participating.
Statistical Analysis
In the current analysis, patients randomized to 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch were stratified according to whether or not they received at least one dose of concomitant memantine (up to 20 mg/day) during the double-blind phase. mg/24 h rivastigmine patch in patients not treated with memantine was compared using analysis of covariance (ANCOVA) with treatment, pooled center, memantine usage and treatment-by-memantine as factors, and the respective baseline as a covariate. To address imbalance in between-group patient demographics and characteristics additional between-group comparisons using the same model were performed for completeness.
Efficacy analyses were based on the Modified Full Analysis Set (MFAS), which included all randomized patients who received at least one dose of study medication and had at least one post-baseline measurement, with missing data imputed using the Last Observation Carried Forward (LOCF) approach.
Sensitivity analyses for the SIB and ADCS-ADL-SIV were conducted using a Mixed-Effect Model Repeated Measure (MMRM) and pattern mixture models. MMRM analyses were based on a repeated measures ANCOVA model with treatment, pooled center, visit, memantine usage, memantine usage-by-treatment, treatment-by-visit, visit-by-memantine usage and visit-by-memantine usage-by-treatment as factors, and the respective baseline total score as a covariate, assuming an unstructured within-subject covariance matrix. Pattern mixture model analyses were based on a repeated measures ANCOVA model with treatment, visit, pooled center, memantine usage, dropout, memantine usage-by-treatment, treatment-by-visit, visit-by-memantine usage, dropout-by-memantine usage, treatment-by-dropout, visit-by-memantine usage-by-treatment and dropout-by-memantine usage-by-treatment as factors, and the respective baseline total score as a covariate, assuming an unstructured within-subject covariance matrix.
Safety evaluations included the incidence of AEs and SAEs in each subgroup. The safety set included all patients who received at least one dose of study medication and had at least one safety assessment post-baseline.
Results
Participants
Of 716 patients randomized to 13.3 mg/24 h or 4.6 mg/24 h rivastigmine patch, 435 (60.8%; 13.3 mg/24 h rivastigmine patch, N=217; 4.6 mg/24 h rivastigmine patch, N=218) received concomitant memantine, regardless of dose or treatment duration.
The study was completed by a similar proportion of patients who received 13.3 mg/24 h rivastigmine patch and memantine (66.8%), 4.6 mg/24 h rivastigmine patch and memantine (65.1%), 13.3 mg/24 h rivastigmine patch without memantine (60.4%) and 4.6 mg/24 h rivastigmine patch without memantine (64.8%). In all subgroups, AEs (13.3 mg/24 h rivastigmine patch and memantine, 18.0%; 4.6 mg/24 h rivastigmine patch and memantine, 12.4%; 13.3 mg/24 h rivastigmine patch without memantine, 24.5%; and 4.6 mg/24 h rivastigmine patch without memantine, 16.9%) and withdrawal of consent (7.4%, 12.4%, 7.9% and 13.4%, respectively) were the primary reasons for discontinuation.
Baseline demographics and characteristics were generally comparable, with the exception that memantinetreated patients tended to be slightly younger, with a longer time since AD diagnosis compared with those who did not receive memantine ( Table 1) . Table 1 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients who received concomitant memantine (Fig. 2) .
Overall, ANCOVA analysis confirmed that there was no significant interaction (p>0. Based on the observed differences at baseline between memantine-treated patients, and patients not receiving memantine, additional ANCOVA analyses were performed, which included baseline MMSE score, age and time since diagnosis of AD as additional covariates. In general, the findings obtained with this model were similar to those obtained with the original ANCOVA model.
Safety and Tolerability
All The incidence of AEs was similar in all subgroups ( Table 2 ). The most common AEs reported by patients who received 13.3 mg/24 h rivastigmine patch and memantine were application site erythema (13.4%), agitation (12.9%), application site dermatitis (9.2%) and fall (9.2%); in those who received 13.3 mg/24 h rivastigmine patch without memantine, AEs were most commonly urinary tract infection (13.0%), application site erythema (13.0%) and agitation (9.4%). In patients randomized to 4.6 mg/24 h rivastigmine patch who received memantine, the most common AEs were agitation (13.8%), application site erythema (12.9%) and urinary tract infection (8.8%); and in those who received 4.6 mg/24 h rivastigmine patch without memantine, AEs were most commonly agitation (14.8%), urinary tract infection (10.6%) and application site dermatitis (10.6%).
The incidence of SAEs was similar in all subgroups (Table 2 ). In both the 13.3 mg/24 h and 4.6 mg/24 h patch groups, the proportion of patients who discontinued due to AEs or SAEs was slightly higher in patients who did not receive concomitant memantine compared with those who received memantine. 
Discussion
The current retrospective analysis investigated the efficacy, safety and tolerability of high-dose (13.3 mg/24 h) rivastigmine patch versus low-dose (4.6 mg/24 h) rivastigmine patch in patients stratified according to their use of concomitant memantine during double-blind treatment. Given the advanced disease stage of the enrolled patient population (mean MMSE score at screening, 8.8) and the indication of memantine for moderate-tosevere AD [5] , it was not unexpected that 61% of this North American patient population received at least one dose of concomitant memantine during the study [13] . Based on our clinical experience, the proportion of patients in this study who received concomitant memantine is consistent with real-world clinical practice in the USA.
Administering agents with distinct mechanisms of action, such as memantine (NMDA receptor antagonist) [5] and rivastigmine (ChEI) [1, 2] in combination may be associated with differential and/or additive effects. In addition to a potential class effect, rivastigmine is unique amongst the approved ChEIs, in that it is the only one to inhibit both acetylcholinesterase and butyrylcholinesterase (donepezil and galantamine are acetylcholinesterase-selective) [18] . In addition, although widely considered to be a symptomatic treatment, studies in rodents have provided evidence for positive effects of rivastigmine on neurodegeneration in the synapse [19, 20] . These mechanistic differences may have biological implications. Given that the efficacy of rivastigmine is dose-dependent and cholinergic deficits increase with disease severity [21, 22] , it seems clinically relevant to investigate the combination of memantine and high-dose rivastigmine in patients with severe AD. Studies with high-dose rivastigmine are made possible via transdermal delivery, which provides access to higher doses than can be reached with oral formulations, due to improved tolerability [23] . To our knowledge, these were the first analyses to investigate the concomitant use of 13.3 mg/24 h rivastigmine patch and memantine in a population with severe AD.
Supporting the primary efficacy findings from the ACTION study [13] , superior efficacy was observed on the SIB with 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients who received concomitant memantine and those not receiving memantine. Significant between-group differences (13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch) were also observed at Week 24 on the ADCS-ADL-SIV in memantine-treated patients, and there was a numerical trend toward greater efficacy with the high-dose 13. With regard to safety, the current analyses suggest that, although there was a slightly higher incidence of AEs among 13.3 mg/24 h rivastigmine patch-treated patients who did not receive concomitant memantine compared with those who received memantine (79.7% versus 71.4%), the safety and tolerability profile of 13.3 mg/24 h rivastigmine patch was generally similar in both subpopulations.
The current post-hoc analyses were intended to be hypothesis-forming, and this should be taken into consideration when interpreting the findings. The ACTION study was not powered to detect effects of memantine use on the efficacy, safety and tolerability of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch.
Although the current analyses suggest there are no additive effects of concomitant treatment with memantine and rivastigmine, additional analyses would be required to confirm these findings. It should be noted that patients were not randomly allocated to memantine treatment; hence there were imbalances between the subpopulations with regard to their baseline characteristics, which may also have influenced findings. However, similar findings were obtained regardless of whether baseline MMSE score, age, and time since AD diagnosis were included as covariates in the statistical model, suggesting these factors do not have a marked impact on the observed results.
The effect of concomitant memantine use on the efficacy, safety and tolerability of 9.5 mg/24 h rivastigmine patch in patients with mild-to-moderate AD has been previously investigated [24, 25] . An open-label study reported no marked differences in the safety or efficacy of combination therapy with 9.5 mg/24 h rivastigmine patch and memantine compared with 9.5 mg/24 h rivastigmine patch alone in patients with mild-to-moderate AD [24] . Furthermore, post-hoc analysis of a 25-week, randomized, open-label study reported a non-significant increase in the incidence of AEs in patients with mild-to-moderate AD treated with 9.5 mg/24 h rivastigmine patch plus memantine, compared with memantine alone (73.3% versus 67.5%) [25] . Overall, there were no significant differences in the efficacy of 9.5 mg/24 h rivastigmine patch between patients receiving memantine and patients not receiving memantine on the Clinical Global Impression of Change, or the MMSE; memantinetreated patients demonstrated significantly greater deterioration on the ADCS-ADL scale compared with those not receiving memantine [25] . The 9.5 mg/24 h rivastigmine patch was not included in the current analysis, as although used during dose titration, it was not a randomized target dose in the ACTION study. During ACTION, the first study of rivastigmine patch in patients with severe AD, 4.6 mg/24 h patch was selected as a low-dose active comparator to fully investigate the efficacy, safety and tolerability of the high-dose 13.3 mg/24 h patch in this patient population [13] . Further, large-scale, randomized, controlled clinical studies would be required to fully investigate the effect of memantine use on the efficacy, safety and tolerability of 13.3 mg/24 h rivastigmine patch (and other patch doses, i.e. 9.5 mg/24 h) in patients with severe AD.
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